Scientists develop off-the-shelf immunotherapy for metastatic kidney cancer

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment—all without the need to customize treatment for each individual patient.

This “off-the-shelf” approach, called AlloCAR70-NKT, could help improve outcomes, reduce complications and expand access for patients with limited treatment options.

“We successfully turned stem cells into powerful cancer-fighting immune cells that can be ready to use for any patient, bypassing the need to engineer each patient’s own cells,” said Dr. Lily Wu, professor of molecular and medical pharmacology and urology at the David Geffen School of Medicine at UCLA and co-senior author of the study.

“This approach overcomes the time delays and safety risks of traditional immunotherapies, especially for patients with aggressive, late-stage disease.”

Sign up for Blog Updates